Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics
ALKS Price/Volume Stats
Current price | $32.18 | 52-week high | $33.71 |
Prev. close | $32.56 | 52-week low | $22.01 |
Day low | $31.83 | Volume | 3,746,800 |
Day high | $32.88 | Avg. volume | 1,699,964 |
50-day MA | $27.81 | Dividend yield | N/A |
200-day MA | $28.39 | Market Cap | 5.37B |
ALKS Stock Price Chart Interactive Chart >
ALKS POWR Grades
- ALKS scores best on the Value dimension, with a Value rank ahead of 98.46% of US stocks.
- ALKS's strongest trending metric is Stability; it's been moving down over the last 175 days.
- ALKS ranks lowest in Stability; there it ranks in the 11th percentile.
ALKS Stock Summary
- ALKS's went public 32.49 years ago, making it older than 83.94% of listed US stocks we're tracking.
- In terms of twelve month growth in earnings before interest and taxes, ALKERMES PLC is reporting a growth rate of -277.65%; that's higher than merely 4.54% of US stocks.
- As for revenue growth, note that ALKS's revenue has grown 40.56% over the past 12 months; that beats the revenue growth of 88.8% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to ALKERMES PLC are ATEN, MDRX, VNDA, AXTI, and CSGS.
- Visit ALKS's SEC page to see the company's official filings. To visit the company's web site, go to www.alkermes.com.
ALKS Valuation Summary
- In comparison to the median Healthcare stock, ALKS's price/sales ratio is 30.95% lower, now standing at 2.9.
- Over the past 243 months, ALKS's price/sales ratio has gone down 29.1.
Below are key valuation metrics over time for ALKS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ALKS | 2023-12-29 | 2.9 | 3.4 | 21.6 | 18.2 |
ALKS | 2023-12-28 | 2.9 | 3.4 | 21.7 | 18.3 |
ALKS | 2023-12-27 | 2.9 | 3.5 | 21.8 | 18.5 |
ALKS | 2023-12-26 | 2.9 | 3.4 | 21.7 | 18.3 |
ALKS | 2023-12-22 | 2.9 | 3.4 | 21.7 | 18.4 |
ALKS | 2023-12-21 | 2.9 | 3.4 | 21.4 | 18.1 |
ALKS Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at 64.4%.
- Its 4 year revenue growth rate is now at 52.95%.
- Its 3 year cash and equivalents growth rate is now at 25.45%.
The table below shows ALKS's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 1,111.795 | 21.044 | -158.267 |
2022-09-30 | 1,131.584 | 51.018 | -129.14 |
2022-06-30 | 1,173.368 | 133.17 | -94.154 |
2022-03-31 | 1,200.866 | 168.539 | -61.654 |
2021-12-31 | 1,173.751 | 101.715 | -48.169 |
2021-09-30 | 1,129.283 | 138.037 | -91.684 |
ALKS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ALKS has a Quality Grade of B, ranking ahead of 88.71% of graded US stocks.
- ALKS's asset turnover comes in at 0.582 -- ranking 63rd of 680 Pharmaceutical Products stocks.
- OTLK, AVEO, and LXRX are the stocks whose asset turnover ratios are most correlated with ALKS.
The table below shows ALKS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.582 | 0.835 | -0.047 |
2021-06-30 | 0.576 | 0.836 | -0.029 |
2021-03-31 | 0.556 | 0.835 | -0.050 |
2020-12-31 | 0.557 | 0.828 | -0.061 |
2020-09-30 | 0.641 | 0.845 | -0.034 |
2020-06-30 | 0.646 | 0.844 | -0.076 |
ALKS Price Target
For more insight on analysts targets of ALKS, see our ALKS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $26.50 | Average Broker Recommendation | 1.88 (Hold) |
Alkermes plc - Ordinary Shares (ALKS) Company Bio
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.
Latest ALKS News From Around the Web
Below are the latest news stories about ALKERMES PLC that investors may wish to consider to help them evaluate ALKS as an investment opportunity.
Equal Opportunity and Respect: Diversity, Inclusion and Belonging at AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility Report NORTHAMPTON, MA / ACCESSWIRE / December 27, 2023 / Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive ... |
Alkermes (ALKS) Outperforms Broader Market: What You Need to KnowAlkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close. |
The Cream Of The Crop: 5 Biotechs That Outrank Most StocksThe top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders. |
11 Most Promising Psychedelic Stocks According to Hedge FundsIn this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […] |
Corporate Governance at AlkermesNORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Board of Directors Our Board is currently comprised of eleven members, each of whom has a term expiring at ... |
ALKS Price Returns
1-mo | 15.34% |
3-mo | 35.44% |
6-mo | 15.30% |
1-year | 14.64% |
3-year | 64.35% |
5-year | -3.51% |
YTD | 16.01% |
2023 | 6.16% |
2022 | 12.34% |
2021 | 16.59% |
2020 | -2.21% |
2019 | -30.87% |
Continue Researching ALKS
Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...